BioXcel Therapeutics, Inc. BTAIQ
0.04
0.00
0.00%
as of 25 Sep
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BTAIQ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 63.52% | 76.98% | 74.14% | 78.16% |
+8 more TTM periods Free account |
|
| (259.62%) | (207.56%) | (167.91%) | (145.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
65.40% | 359.26% | 770.98% | (996.07%) | |
Average Days of Receivables |
40.34 | 115.94 | 132.47 | 0.00 | |
Free Cash Flow per Share |
(1.68) | (2.43) | (4.72) | (4.10) | |
Free Cash Flow |
(50.90) | (57.38) | (57.61) | (58.21) | |
Piotroski F-Score |
4.00 | 2.00 | 3.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(1,823.21%) | (481.14%) | (134.34%) | (101.20%) | |
Accounts Receivable Turnover |
6.97 | 6.21 | 1.23 | 0.00 | |
Accounts Payable Turnover |
0.02 | 0.03 | 0.01 | 0.06 | |
Inventory Turnover |
0.70 | 0.76 | 0.23 | 0.97 | |
Average Days of Payables |
19,700.56 | 13,695.51 | 32,718.69 | 6,168.99 | |
Days of Inventory on Hand |
506.59 | 421.48 | 1,606.89 | 173.97 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,905.66% | 4,213.53% | 4,711.99% | 3,916.36% | |
Selling, General and Administrative Expense of Revenue |
3,176.01% | 3,233.24% | 3,192.21% | 2,763.83% | |
Share Based Compensation of Revenue |
245.82% | 444.41% | 431.00% | 281.65% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.76 | 0.82 | 0.85 | |
Depreciation/Fixed assets |
2.27 | 2.41 | 1.71 | 1.22 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.02 | 0.03 | 0.05 | 0.05 | |
Operating CF per Share |
(1.68) | (2.43) | (4.72) | (4.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(9,549.87%) | (11,078.53%) | (10,887.38%) | (9,070.61%) |
Columns are period end dates